VHT - Vanguard Health Care ETF
| Assets | $14.32B |
| NAV | $237.45 |
| Expense Ratio | 0.10% |
| PE Ratio | 25.50 |
| Beta (5Y) | 0.80 |
| Dividend (ttm) | $2.90 |
| Dividend Yield | 1.22% |
| Ex-Dividend Date | Mar 26, 2021 |
| 1-Year Return | - |
| Trading Day | April 21 |
| Last Price | $240.91 |
| Previous Close | $237.55 |
| Change ($) | 3.36 |
| Change (%) | 1.41% |
| Day's Open | 238.04 |
| Day's Range | 238.04 - 241.01 |
| Day's Volume | 268,592 |
| 52-Week Range | 179.61 - 241.01 |
Fund Description
The investment seeks to track the performance of a benchmark index. The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index (IMI)/Health Care 25/50, an index made up of stocks of large, mid-size, and small U.S. companies within the health care sector, as classified under the Global Industry Classification Standard (GICS). The Advisor attempts to replicate the target index by seeking to invest all, or substantially all, of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. The fund is non-diversified.
| Asset Class Equity | Sector Biotech |
| Region North America | Inception Date Jan 26, 2004 |
| Exchange NYSEARCA | Ticker Symbol VHT |
| Index Tracked MSCI US Investable Market Health Care 25/50 Index | |
Top 10 Holdings
41.06% of assets| Name | Symbol | Weight |
|---|---|---|
| Johnson & Johnson | JNJ | 7.96% |
| UnitedHealth | UNH | 6.50% |
| Abbott Laboratories | ABT | 3.91% |
| Pfizer | PFE | 3.71% |
| Merck | MRK | 3.59% |
| AbbVie | ABBV | 3.52% |
| Thermo Fisher Scientific | TMO | 3.33% |
| Eli Lilly | LLY | 2.96% |
| Medtronic | MDT | 2.93% |
| Amgen | AMGN | 2.67% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 26, 2021 | $0.635 | Mar 31, 2021 |
| Dec 17, 2020 | $0.882 | Dec 22, 2020 |
| Sep 11, 2020 | $0.631 | Sep 16, 2020 |
| Jun 22, 2020 | $0.756 | Jun 25, 2020 |
| Mar 10, 2020 | $0.445 | Mar 13, 2020 |
| Dec 16, 2019 | $0.717 | Dec 19, 2019 |
UnitedHealth agreed to buy Change Healthcare for $7.84 billion in cash.
These biotech stocks allow you to profit off the innovations that are giving us longer, healthier lives through the companies that make them. The post 5 Rational Biotech Stocks to Buy appeared first on ...
Chart patterns suggest that focus should expand from the biotechs and drug makers to other niche healthcare segments.
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.
Philip Morris’s stock is dropping today along with the broad market as the company that makes Marlboro cigarettes told Irish retailers it made a “mistake” by showing an advertisement in the trade press ...
The healthcare space is heated up with players rushing to come up with a vaccine for COVID-19.
The coronavirus pandemic put healthcare exchange-traded funds (ETFs) in the forefront as medical providers are an essential component in the global market landscape. However, investors shouldn’t suck up...
The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.
Along with molecular testing, antibody testing is gaining immense prominence as economies are struggling to reopen.
While stocks struggled anew on Wednesday, relinquishing most of the gains of the prior day, amid poor data and renewed coronavirus concerns, the healthcare sector had some shining stars. Shares of Johns...
It seems that testing for COVID-19 is the major key in controlling the outbreak and helps in making decisions like treatment protocols, resource allocation and drafting the right healthcare policies.
Coronavirus fears are spreading, but it’s opening up options for disruptive technology to show its stuff in the wake of the outbreak.
Investors have shunned healthcare stocks and sector-related ETFs during a U.S. presidential election year, but things might turn out differently this time around.
In an update to his original November strategy of getting investing in health care, the Viper Report’s Tom Aspray shares his technical outlook on three of the sector’s key ETFs.
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
As the major averages continue to make new highs, one sector that stood out in November is still acting strong.
Income-minded investors who are looking for better dividend growth opportunities can consider targeted exchange traded fund plays to hone in on potentially worthwhile areas, notably those in the healthc...
The healthcare sector has been a sure, but steady performer and a common safe haven sector when stocks head to the downside, but will future regulatory risks expose too much froth via overvaluation in t...
By BOOX Research VHT tracks a basket of 402 Health Care sector stocks. We contrast VHT to the larger and more actively traded XLV ETF with data showing the Vanguard fund outperforming over various time ...
The major breakouts in several of the health care ETFs were a reason to buy in November and Tom Aspray takes a new look at their charts.
Merger and acquisitions (M&A) activity within the healthcare industry heightened last year, according to recent research data and this could feed into gains for M&A and healthcare-focused ETFs for trade...
While all eyes are on the fate of the phase one trade deal between the United States and China, Healthcare sector can forget tension and soar higher in 2020 even if there is no deal.
With the major averages at new all-time highs, Tom Aspray still likes the potential of three health care ETFs. He explains why he likes these three and proposes a strategy for getting invested in these...
Biotechnology stocks have been outperforming over the past month, but ETF investors seem disinterested and are even trimming exposure to this sector.
The Vanguard Health Care ETF (VHT) and other healthcare ETFs have been trading higher amid news that U.S. health officials may finally have a potential discovery in the vaping illness outbreak that’s ki...
Some market watchers believe that investors are overlooking earnings weakness and betting big on stocks buoyed by hopes. However, it isn't a weak earnings season for all sectors.
These exchange-traded funds offer investors an easy way to potentially profit from growth in the healthcare sector.
With earnings surprise in the cards, the healthcare sector is expected to witness modest earnings growth of 0.3% in the third quarter, suggesting some room for potential upside for healthcare ETFs.
Johnson & Johnson continued its long streak of earnings beat and outpaced revenue estimates. It also raised its guidance for the full year.
The healthcare sector, led by ETFs like the SPDR Health Care ETF (XLV), is helping to drive stocks higher on Tuesday, along with technology. XLV is up over 1.67%, as reported earnings from several major...
While markets have had a choppy week, 2019 has revealed some outstanding performers in certain underrated sectors. Technology and healthcare have been solid spaces to invest in, despite how the headline...
Vanguard Health Care Index Chart – NYSEARCA: VHT Today’s chart of the day is the Vanguard Health Care Index ETF (VHT), a broad index across the sectors various industries.
The electronic cigarette market is a burgeoning global industry that includes vaping, and is forecast to expand from less than $10 billion now to over $50 billion by 2025, causing many to consider inves...
Bullish chart patterns suggest that active traders will be looking for health care stocks to make a major long-term move higher.
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
Biotech stocks fall after Trump promises executive order drug prices
CNBC's Meg Tirrell reports on the dip in biotech stocks after President Donald Trump promised that an executive order on drug prices is coming.
Health care's sharp drop comes as investors worry that left-leaning policy ideas like universal health coverage are gaining support.
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.